Delivering the promise of the Decade of Vaccines: Opportunities and challenges in the development of high quality new vaccines

The Decade of Vaccines (DoV) initiative, launched in 2010, has as its mission to extend, by 2020 and beyond, the full benefits of immunization to all people, regardless of where they are born, who they are, or where they live. Through their life-saving vaccines, the research-based vaccine companies represented by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and the Biotechnology Industry Organization (BID) make a major contribution toward this vision. In this article, we begin by summarizing progress made over the past three decades in research and development (R&D) of new and future vaccines, and identify the opportunities and challenges faced by the research-based vaccine industry. We then review the Global Vaccine Action Plan (GVAP) [1] and provide IFPMA and BIO consensus perspectives on its six strategic objectives. Finally, we identify policy measures to support R&D of, and access to, high-quality, innovative vaccines. (C) 2012 Elsevier Ltd. All rights reserved.